Osteologix develops pharmaceutical products for bone and cartilage disorders addressing large markets and offering low-risk development. The therapies developed by Osteologix represent valuable solutions to the patients suffering from diseases of bone and cartilage, and they represent cost-effective therapeutic options for the healthcare providers. Osteologix's lead compound for prophylaxis and treatment of osteoporosis is being developed for multiple clinical indications. The main program is aimed at osteoporosis. Additional programs are aimed at secondary indications in metabolic bone diseases and OA exploiting maximal synergies with the Osteoporosis program.

Prolexys Pharmaceuticals is a developer of cancer and cardiovascular small molecule drugs.

Aderis Pharmaceuticals, formerly Discovery Therapeutics, develops and commercializes small molecule, receptor-specific therapeutics for the treatment of central nervous system, cardiovascular and renal diseases.

Humanetics is a clinical stage pharmaceutical company that works on solid tumor cancers and developing countermeasures for radiation exposure. The company creates radiation modulators intended to improve radiation treatments for cancer patients and protect normal tissues from radiation damage. Humanetics' primary product, BIO 300, is under development for use in oncology to sensitizing tumor cells to radiation, and for inflammatory lung diseases as a countermeasure for radiation exposure. It was founded in 1988 and is based in Minneapolis, Minnesota.

Resolvyx Pharmaceuticals is a company focused on the development of pharmaceutical solutions within the healthcare sector. The company's main offerings include research and development of medications and treatments aimed at improving patient health outcomes. These products are designed to address various medical conditions, providing therapeutic benefits to those in need. It is based in Bedford, Massachusetts.

Immunomic Therapeutics focuses on nucleic acid immunotherapy platforms within the oncology sector. The company develops vaccines using its Universal Intracellular Targeted Expression (UNITE) platform, which is designed to elicit immune responses against various diseases. Its pipeline includes programs for cancer, animal health, infectious diseases, and allergies, with a focus on therapies that produce antibodies, cytokines, and immunological memory. It was founded in 2005 and is based in Rockville, Maryland.